A rterial stiffness is an age-related trait that has been long recognized as an important risk factor for cardiovascular disease. Carotid-femoral pulse wave velocity (PWV) is generally considered the gold standard measure of aortic stiffness in clinical practice, as well as in research studies.
A rterial stiffness is an age-related trait that has been long recognized as an important risk factor for cardiovascular disease. Carotid-femoral pulse wave velocity (PWV) is generally considered the gold standard measure of aortic stiffness in clinical practice, as well as in research studies. [1] [2] [3] PWV is a risk factor for the development of hypertension in normotensive populations 4, 5 and an independent risk factor for coronary artery disease and stroke in healthy subjects. 6 In addition, higher PWV is a significant predictor of mortality in the general communitydwelling population, 7, 8 in hospitalized older subjects, 9 as well as in patients with hypertension, 10 and end-stage renal disease.
11
Despite its clinical significance, 12, 13 essentially no information is available on (1) the pattern and rate of longitudinal changes in PWV within individuals of a general community-dwelling population of a broad age spectrum, and (2) how longitudinal PWV trajectories are affected by blood pressure and other cardiovascular risk factors. Cross-sectional and short-term longitudinal studies observed that age and blood pressure are major correlates of arterial stiffness, [14] [15] [16] [17] [18] [19] with little difference between sexes, although some studies have reported higher PWV in men. 18, 19 The Baltimore Longitudinal Study of Aging (BLSA), a large prospective cohort study with repeated measures of PWV and risk factor assessment, provides an excellent opportunity to examine the pattern and the rate of longitudinal change in PWV within and among individuals. We analyzed data from the BLSA aiming to (1) examine pattern and rate of longitudinal trajectories in PWV and determine whether these trajectories differ between men and women, and (2) examine whether blood pressure and other cardiovascular risk factors affect the longitudinal rates of change in PWV. Such information is not only crucial with respect to elucidating mechanisms that underlie arterial stiffening and predominately systolic hypertension that accompanies advancing age but also to the design of interventions and clinical trials aimed at reducing or slowing arterial stiffness. 20 
Methods

Study Sample
The BLSA is a prospective study of community-dwelling volunteers who undergo ≈2.5 to 3 days of medical, physiological, and psychological examinations at regular intervals. 21 Between 1988 and 2013, repeated PWV measurements and medical, physiological assessments are performed on a subset of 943 BLSA participants. Those selected for the present analysis are chosen on the basis of having repeated PWV and blood pressure measurements over time. Written, informed consent is obtained from all study participants. The BLSA has continuing approval from the Institutional Review Board of the MedStar Research Institute, and the protocol for the present study is also approved by the Institutional Review Board of the Johns Hopkins School of Medicine. The final sample consisted of 775 subjects and a total of 2400 repeated measures; a total of 168 subjects are excluded for evidence of clinical atherosclerosis and or aberrant PWV as described in the Methods in the online-only Data Supplement. Distribution of participants and follow-up visits by age at entry is shown in Table S1 in the online-only Data Supplement.
Carotid-Femoral PWV
Carotid-femoral PWV was calculated as the distance traveled by the pulse wave divided by the time difference between the feet of carotid and femoral arterial waveforms gated to ECG. The distance traveled by the pulse wave was measured to the nearest centimeter with an external tape measure over the body surface. Because body surface measurements might result in overestimation of distance, and subsequently PWV, in those with larger body habitus, we performed a supplementary analysis using an alternative estimation of distance derived from body height at initial visit (distance=first height×0.29). 22 Given the long follow-up period, the device used to record arterial waveforms changed. In the present analysis, different devices had been used: (1) transcutaneous Doppler probes (model 810A; 9-10-MHz probes; Parks Medical Electronics, Inc, Aloha, OR); (2) Complior SP device (Artech Medical, Paris, France) 2, 23 ; and (3) SphygmoCor system (AtCor Medical, Sydney, Australia). 24 Refer to the Methods in the online-only Data Supplement for a detailed description of the PWV measurement protocol and process of standardization across the 3 devices.
Blood Pressure
Oscillometric brachial blood pressure was measured at the time of PWV measurement. Hypertension was defined as blood pressure ≥140/90 mm Hg or the use of antihypertensive medications (see Methods in the online-only Data Supplement). Subjects in each visit were categorized on the basis of their systolic blood pressure (SBP) into 3 categories: <120, 120 to 139, and ≥140 mm Hg based on the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 25 
Clinical Variables
Height and weight were measured on all patients. Body mass index was determined as kilograms per square meter. Waist circumference (WC) was measured as the minimal abdominal circumference between the lower edge of the rib cage and the iliac crests. Subjects were classified to ever versus never a smoker. The use of medications was determined at each study visit. Diabetes mellitus was defined as meeting the 2011 American Diabetes Association criteria 26 or the use of diabetes mellitus medications. Hypercholesterolemia was defined as total serum cholesterol of 200 mg/dL or the use of lipid-lowering treatment.
Laboratory Studies
Fasting plasma glucose, triglycerides, total cholesterol, and highdensity lipoprotein-cholesterol were measured. Low-density lipoprotein-cholesterol concentrations were estimated using the Friedewald formula. 27 Refer to the Methods in the online-only Data Supplement for further details.
Statistical Analysis
Baseline characteristics for men and women were reported and compared by Student t test and χ 2 test. Linear mixed-effect models were implemented to assess the rate and the pattern of longitudinal change in PWV and the impact of SBP on these trajectories. The linear mixed-effect model easily accommodates unbalanced, unequally spaced observations and, consequently, is an ideal tool for analyzing longitudinal changes in data from an observational study, such as the BLSA 28 ; all models included date of first visit to adjust for cohort and period effects. Age was expressed as first-age (age at entry), and time (follow-up time), to differentiate cross-sectional differences from longitudinal changes over time. Sex difference was tested by running the model in the pooled data for men and women with sex, sex×first-age, and sex×time interaction terms. We fitted models in different age subgroups to identify the age after which sex difference became significant. Models were then run on men and on women, separately. Predicted PWV, using sex-age-specific mean values for SBP and heart rate (HR), and its rate of change per decade were plotted against age in men and in women. Additional models tested for the cross-sectional and longitudinal association with other cardiovascular health-related covariates by including time-covariate interaction terms. Significant interaction terms for variables affecting longitudinal rates of changes in PWV were included in the final model. Linear mixed-effect regression with categories of SBP was performed to further assess the difference in the longitudinal change in PWV between SBP categories after applying backward elimination of statistically nonsignificant terms in the full model ( Table 3) . Quality of models was tested by the correlation between predicted and observed PWV. All analyses were done using SAS for Windows (version 9.2; SAS Institute Inc, Cary, NC).
Results
Men and women had similar age distribution and length of follow-up (Table 1) . Compared with women, men were taller, heavier, had higher BMI, larger WC, and were more likely to have ever smoked. Men also had lower HR and higher PWV, SBP, diastolic blood pressure, and MAP. Men were more likely to be on antihypertensive medications; however, there was no sex difference in the use of antihypertensive medications among hypertensive subjects at baseline or by the end of follow-up. Men had lower HDL-cholesterol and higher triglycerides and glucose. Antihyperlipidemic and anti-diabetes mellitus medication use were similar in both sexes (Table 1) .
Adjusting for SBP, HR, antihypertensive medication use, and WC, we found no overall difference in PWV between men and women when the full age spectrum was considered (β=0.12; P=0.298). However, we found significant firstage×sex (β=0.25; P<0.0001) and time×sex (β=0.27; P=0.04) interactions (Table S2) indicating that sex differences emerged with increasing age with men having steeper increase of PWV with age than women. To follow up on this finding, we fitted age-stratified models and found that, indeed, men compared with women had significantly higher PWV only after the age of 50 years (β=0.305; P=0.045). To investigate whether sex differences were a result of falsely elevated PWV in men because of more prevalent central, android obesity, we repeated the analysis with PWV calculated using distance estimated as 29% of height at first visit (see Methods in the online-only Data Supplement) and found similar results (Table S3) .
When we fitted separate models for men and women, we found that in both sexes PWV was higher with older age and increased longitudinally within a given individual over time. The first-age 2 and first-age×time interaction terms were significant in men and in women indicating an accelerating increase in PWV with aging. However, men had a more pronounced acceleration with aging evidenced by a significant first-age 2 ×time interaction ( Table 2) . As expected, SBP, HR, and WC were significantly and independently associated with higher PWV in both men and women, whereas antihypertensive medications were not. To illustrate sex differences in changes in PWV with aging, model-predicted PWV for age-sex-specific mean values for SBP and HR were plotted against age for men and women, separately ( Figure 1A ). Note the accelerating rates of PWV increase per decade in men beyond the fifth decade ( Figure 1B) .
We tested for the association of PWV with SBP and other traditional cardiovascular risk factors in additional models (Table 3 ). Higher SBP was associated with higher rate of PWV increase, as evidenced by a significant SBP×time interaction in both men (β=0.17; P=0.004) and women (β=0.13; P=0.0167). Note that in men, there was a cross-sectional independent association between PWV and triglycerides levels, whereas there was a cross-sectional association of HR, WC, and fasting glucose with PWV in women. Interestingly, in women higher WC was associated with a higher rate of PWV increase over time, evidenced by a significant WC×time interaction term. There was a trend toward an association between nonwhite race and higher PWV that did not reach statistical significance. There was no direct association with other major traditional cardiovascular risk factors, such as smoking and LDL.
We further dissected into the association between SBP and PWV by stratifying SBP into 3 categories. Interestingly, in both men and women not only SBP≥140 mm Hg but also SBP of 120 to 139 mm Hg was associated with larger longitudinal increase in PWV compared with SBP<120 mm Hg in a dose-dependent fashion (Table 4) . Furthermore, in men with SBP≥140 mm Hg, the magnitude of PWV increase over time accelerated with advancing age as evident by a significant first-age×time×SBP category-3 interaction term (Table 4) . Model-predicted PWV and its rate of change per decade were plotted against age for the SBP categories in men and in women (Figure 2A and 2B). Note in Figure 2B that among men, SBP of 120 to 139 mm Hg was consistently associated with faster rates of PWV increase over time (0.3-1.7 m/s per decade) compared with that at SBP<120 mm Hg (−0.2 to 1.3 m/s per decade). Also, note in Figure 2B that among men with SBP≥140 mm Hg is not only associated with higher rate of change over time than the other SBP categories but also that the rate of increase accelerated over time beyond the age of 50 years illustrating the first-age×time×SBP category-3 interaction shown in Table 4 . Similarly, in women there was a separation in the trajectories of PWV among the SBP subgroups ( Figure 2C ). It is worth noting that the rates of PWV increase in women with SBP≥140 mm Hg were similar to that of SBP of 120 to 139 mm Hg and relatively more constant across the age spectrum compared with men.
Discussion Principle Findings
This is the first extended longitudinal study of PWV in the general population of men and women of a broad age spectrum and extensive clinical information available. We report rates of PWV increase per decade for men and women over a broad age range. Knowing the magnitude and patterns of PWV increase over time is crucial to better estimate the duration and sample size of clinical trials aimed at reducing or slowing arterial stiffening. One novel finding of this study is that men compared with women had steeper longitudinal increase in PWV with aging leading to higher PWV beyond the fifth decade. Another novel finding is that elevated SBP, even in the prehypertensive range, is associated with higher rates of PWV increase that persisted after adjusting for antihypertensive medications and other traditional cardiovascular risk factors.
Differential Rate of Change in PWV Between Men and Women Leads to Sex Differences
We observed sex differences in PWV at higher but not younger age resulting from accelerating rates of PWV increase with aging in men compared with slower rates of increase in women. This difference was independent of distance measurement errors because of sex differences in body habitus. Previous longitudinal studies did not report age-sex-specific rates of change in PWV, 5,29,30 hence did not reveal such an *P<0.05 for the main term before inclusion of interaction terms, note that because of the significant interaction between first-age and time, correlation coefficients for the main terms cannot be interpreted separately from the interaction term.
Correlation between observed and model-predicted PWV was 0.77 and 0.80 in men and in women, respectively. observation. On the one hand, cross-sectional studies, limited by their design, report controversial results on sex differences in PWV with only 15 of 54 studies assessed in a systemic review showed higher PWV in men. 19 It is not clear why women did not experience acceleration in the rates of PWV increase in the higher decades; however, this might be linked to a similar pattern of sex differences in aortic remodeling 31 with women having slower rates of aortic dilatation, another aging phenomenon that accompanies arterial stiffness.
Arterial Stiffness and SBP: A Vicious Cycle?
The relationship between arterial stiffness and blood pressure is complex. On the basis of the findings of this longitudinal analysis, we conclude that higher SBP was associated with accelerated rate of PWV increase, and the results of previous reports of higher PWV predicting the longitudinal increase in SBP, 4, 5 the association between blood pressure and arterial stiffness may be best described as feed forward (ie, a vicious cycle). Our current findings of a dose-dependent association of SBP with higher rates of PWV increase in SBP≥140 mm Hg compared with 120 to 139 mm Hg and <120 mm Hg provide a rather strong indication of a potential role of higher SBP in accelerated arterial stiffness. Specifically in men, this dose dependence of SBP on PWV and age gives rise to a triple interaction among age, time, and SBP (Table 4 ; Figure 2A and 2B). In other terms, the impact of high SBP (≥140 mm Hg) on the rate of PWV increase over time in men increases with each successive decade. In contrast, in Models were adjusted for variables shown, smoking, low-density lipoprotein, triglycerides, high-density lipoprotein, glucose, creatinine, antihypertensive medications, antihyperlipidemic medications, and initial date of visit; results were reported for terms with P<0.1. First-age and time interaction with covariates were tested and only significant interaction terms were included in the final model. PWV indicates pulse wave velocity. *P<0.05 for the main term before inclusion of interaction terms (see explanation in the footnote of Table 2 ). Cor (observed and predicted) was 0.85 and 0.83 in men and in women, respectively. Table 3 with P<0.05. β is the unstandardized regression coefficients. PWV indicates pulse wave velocity; and SBP, systolic arterial pressure. *P<0.05 for the main term before inclusion of interaction terms, correlation coefficients for the main terms cannot be interpreted separately from those for the interaction terms.
†Coefficients for time and first-age are calculated for 10-year increments. Cor (observed and predicted) was 0.85 and 0.83 in men and in women, respectively. The findings of this study are in agreement with a previous 2-wave longitudinal study showing that PWV accelerates at a greater rate in uncontrolled hypertensive patients compared with patients with controlled hypertensive and normotensive subjects. 29 However, the aforementioned study did not address the association between SBP and rate of PWV increase in the prehypertensive range. On the other hand, our findings differ from a recent report from Framingham study where antecedent SBP was not independently associated with PWV measurement at a future visit. 5 However, PWV was measured only 2×, 7 years apart in the cited study. It is possible that the longer follow-up period and multiple repeated measures of PWV at shorter intervals of 2.5 years on average might have increased the power to detect the effect of SBP on the rate of PWV change with time.
Central Obesity in Women Is Associated With Arterial Stiffness
We observed an association between WC and higher rates of PWV increase in women with higher WC having an additive rather than synergistic effect with SBP. This association between PWV and WC was attenuated but remained significant when PWV was calculated using body height-derived distance (Table S3 ). This indicates that overestimation of distance, and subsequently PWV, using body surface measurement explained a part, but not all of the association of WC with PWV. We had previously found that metabolic syndrome amplifies the age-associated increase in arterial stiffness assessed by other measurements, such as carotid distensibility. 32 We have also found that the cross-sectional association between adiposity and arterial stiffness is stronger in women than in men. 33 A prior report has shown that weight increase is associated with an increase in PWV in healthy subjects. 30 These findings suggest a role for obesity and its metabolic derangements in the pathogenesis of arterial stiffness and encourage close examination of this relationship, while introducing another benefit for weight loss beyond its already well-established and impressive benefits.
Dissociation of Longitudinal Changes in Arterial Stiffness From Other Cardiovascular Disease Risk Factors
Our longitudinal study results confirm the recently reviewed findings of prior cross-sectional studies 19 that show dissociation or at the maximum minimal association between arterial stiffness and traditional cardiovascular risk factors except for age and SBP. 19 We observed a trend toward higher PWV in nonwhite, mainly black, subjects that is consistent with previous literature. 34 This might provide an explanation of the higher incidence of hypertension in blacks; further studies with larger representation of minorities are needed to evaluate for racial differences in the longitudinal change in PWV. The association we observed with triglycerides and glucose was cross sectional only that make them less likely causative agents. These facts seem to negate a major role of atherosclerosis in arterial stiffness in this healthy population free of clinical atherosclerosis throughout the period of the study. The exclusion of any subject who developed clinical atherosclerosis at enrollment or during follow-up in the recent study reduced the potential effect of plaque burden on the Our study has some limitations that should be considered while interpreting the results. First, the relatively small sample size, especially when categorizing blood pressure subgroups, might limit the use of the absolute values of the rates of PWV change; however, the frequent observations and long followup insured enough power to detect dose-dependent effect of SBP on PWV increase. Second, estimation of PWV using body surface distance might introduce measurement errors and produce overestimation of PWV caused by central obesity. However, adjusting all models to WC should minimize this effect; in addition, using body height-derived distance measurements showed similar findings.
Perspectives
Age and SBP are the main longitudinal determinants of PWV, and the effect of SBP on PWV trajectories exists even in the prehypertensive range. Arterial stiffness and SBP interact in a vicious cycle; hence, the improvement observed in PWV beyond blood pressure control in pharmacological clinical trials [35] [36] [37] might be interpreted as winding down of this vicious cycle. Our results emphasize the importance of both blood pressure control and the development of novel interventions at the level of central arteries to limit the progress of this detrimental vicious cycle. 
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METHODS
Exclusion criteria
One hundred and thirty-four subjects were excluded because of evidence of overt coronary artery disease (n=104), peripheral vascular disease (n=13), stroke (n=1), or combination of these conditions (n=48) at baseline or during follow up. Coronary artery disease was defined by history of angina pectoris, documented myocardial infarction, documented percutaneous cardiac intervention or cardiac bypass surgery, or major Q waves on resting electrocardiograms (Minnesota Code 1:1 or 1:2).Peripheral vascular disease was defined as having symptoms of intermittent claudication. Stroke was defined per reported history.
In 34 subjects, 39 measurements were excluded from the analyses because of aberrant PWV readings defined as more than 5 m/s (two standard deviations) difference in PWV from the preceding or following visits for that subject. This implied excluding18 subjects who had only two visits that where 5m/s apart. Thus, the final sample included 775 men and women with a total of 2400 measurements and a number of follow up visits ranging between 2 and 9 per subject. Distribution of participants and follow ups visit by age at entry is shown in Supplemental Table 1 .
Carotid-femoral Pulse wave velocity
Carotid-femoral PWV and oscillometric blood pressure were measured after the subjects had rested in the supine position in a quiet room for at least 10 min. Subjects abstained from food or from drinking coffee or other caffeine-containing beverages for at least 45 min before performance of the PWV measurements. PWV was calculated as the distance traveled by the pulse wave divided by the time difference between the feet of carotid and femoral arterial waveforms gated to electrocardiogram. The distance traveled by the pulse wave was measured to the nearest centimeter with an external tape measure over the body surface. This distance was measured by subtracting the distance between the manubrium and the carotid sampling site from the sum of the distances between the manubrium and the umbilicus and, between the umbilicus and the femoral sampling site. PWV measurements were repeated 3 times in each visit and the average was used. An alternative estimation of distance used an approximate estimation of the distance based on body height at initial visit (distance=first height ×0.29) to explore the effect of measurement error that might stem from doming of abdomen with central obesity 1 . Over the long follow up period, the device used to record arterial waveforms changed. In the present analysis different devices had been used: 1. Transcutaneous Doppler probes (model 810A, 9 to 10-Mhz probes, Parks Medical Electronics, Inc., Aloha, Oregon) 2. Complior SP device (Artech Medical, Paris, France) 2, 3 , and 3.SphygmoCor system (AtCor Medical, Sydney, Australia) 4 . Measures were standardized across the three devices as described in supplemental methods.
PWV measurements standardization
Three different devices have been used to record arterial waveforms over the long follow up period: 1. Transcutaneous Doppler probes (model 810A, 9 to 10-Mhz probes, Parks Medical Electronics, Inc., Aloha, Oregon) was used from 1988 to 2003 as previously described 5 , 2. Complior SP device (Artech Medical, Paris, France) was used from 2003 to 2010 as previously described 2, 3 , and 3.SphygmoCor system (AtCor Medical, Sydney, Australia) has been used since 2011 as previously described 4 . Head-to head comparison between Complior and SphygmoCor and multivariate regression analyses were done to assess differences among readings due to different devices. Readings performed by SphygmoCor were estimated to be 1 m/s higher than those done with devices used earlier and were independent of other covariates the different and correction to the old studies were made accordingly. Our estimates of device differences were lower than estimates provided by a previous report showing a difference of 1.7 m/s 6 . All analyses performed in this manuscript were also performed using the original PWV measurements with very similar results. Antihypertensive medications Anti-hypertensive medications were defined as thiazide and non-thiazide diuretics, combination thiazide drugs, nitrates, β-blockers, calcium channel blockers, peripheral vasodilators, angiotensin-converting enzyme inhibitors, central and peripheral antihypertensive agents, and combinations of these drugs. Use of these medications was determined at each visit.
Laboratory studies
Blood samples were drawn from the antecubital vein between 7 and 8 AM after an overnight fast. Subjects were not allowed to smoke, engage in physical activity, or take medications before the sample was collected. Concentrations of plasma triglycerides (TG) and total cholesterol were determined by an enzymatic method (Abbott Laboratories ABA-200 ATC Biochromatic Analyzer, Irving, TX). The concentration of high-density lipoprotein (HDL) cholesterol was determined by a dextran sulfate-magnesium precipitation procedure 7 . Lowdensity lipoprotein (LDL) cholesterol concentrations were estimated by using the Friedewald formula 8 . The fasting plasma glucose concentration was measured by the glucose oxidase method (Beckman Instruments, Inc., Fullerton, CA).
Statistical analysis
Selection of blood pressure parameter Models were tested using blood pressure as 1) SBP and DBP, and 2) MBP and Pulse pressure. Only SBP and PP predicted the longitudinal increase in PWV, in the first and second method, respectively. Since, PP is an arithmetic derivative of SBP and DBP and that DBP did not have predictive value, we elected to utilize SBP as the main driver of the association between blood pressure and PWV.
Adjustment for antihypertensive medications
The effect of antihypertensive medications on PWV was assessed using linear mixed-effects models that account for the use of antihypertensive medication on PWV at each visit. In alternative analysis, we examined the effect of antihypertensive medications by including a variable for the use of these medications at entry, and another for the introduction of medications during follow up (Table S4) . 
